Latest Insider Transactions at Macrogenics Inc (MGNX)
This section provides a real-time view of insider transactions for Macrogenics Inc (MGNX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MACROGENICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MACROGENICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 04
2024
|
Thomas Spitznagel Sr VP, Technical Ops |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+35.32%
|
$110,000
$11.5 P/Share
|
|
Feb 26
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
SELL
Open market or private sale
|
Direct |
16,124
-64.45%
|
$274,108
$17.22 P/Share
|
|
Feb 22
2024
|
Ezio Bonvini Sr VP, Research & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,366
-8.49%
|
$159,222
$17.11 P/Share
|
|
Feb 22
2024
|
Ezio Bonvini Sr VP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
28,125
+20.32%
|
-
|
|
Feb 22
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
10,126
-28.81%
|
$172,142
$17.11 P/Share
|
|
Feb 22
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
26,250
+42.76%
|
-
|
|
Feb 15
2024
|
Stephen L. Eck Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,872
-41.22%
|
$116,824
$17.4 P/Share
|
|
Feb 15
2024
|
Stephen L. Eck Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,670
+50.0%
|
-
|
|
Feb 15
2024
|
Lynn Cilinski VP, Controller and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,378
-27.68%
|
$40,426
$17.4 P/Share
|
|
Feb 15
2024
|
Lynn Cilinski VP, Controller and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,668
+43.7%
|
-
|
|
Feb 15
2024
|
Scott Koenig President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,349
-1.31%
|
$243,933
$17.4 P/Share
|
|
Feb 15
2024
|
Scott Koenig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
42,341
+3.73%
|
-
|
|
Feb 15
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,441
-33.3%
|
$75,497
$17.4 P/Share
|
|
Feb 15
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
13,336
+50.0%
|
-
|
|
Feb 15
2024
|
Ezio Bonvini Sr VP, Research & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,871
-6.67%
|
$99,807
$17.4 P/Share
|
|
Feb 15
2024
|
Ezio Bonvini Sr VP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,670
+15.93%
|
-
|
|
Feb 15
2024
|
Thomas Spitznagel Sr VP, Technical Ops |
SELL
Payment of exercise price or tax liability
|
Direct |
5,020
-37.64%
|
$85,340
$17.4 P/Share
|
|
Feb 15
2024
|
Thomas Spitznagel Sr VP, Technical Ops |
BUY
Exercise of conversion of derivative security
|
Direct |
13,336
+50.0%
|
-
|
|
Feb 15
2024
|
James Karrels SVP, CFO and Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
5,327
-2.58%
|
$90,559
$17.4 P/Share
|
|
Feb 15
2024
|
James Karrels SVP, CFO and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
15,003
+6.76%
|
-
|
|
Feb 15
2024
|
Eric Blasius Risser Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,879
-8.29%
|
$99,943
$17.4 P/Share
|
|
Feb 15
2024
|
Eric Blasius Risser Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,670
+19.03%
|
-
|
|
Feb 07
2024
|
Ezio Bonvini Sr VP, Research & CSO |
SELL
Open market or private sale
|
Direct |
3,334
-4.47%
|
$60,012
$18.0 P/Share
|
|
Feb 05
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
SELL
Open market or private sale
|
Direct |
76,251
-85.66%
|
$1,220,016
$16.5 P/Share
|
|
Feb 05
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
76,251
+36.15%
|
$762,510
$10.83 P/Share
|
|
Feb 01
2024
|
Ezio Bonvini Sr VP, Research & CSO |
SELL
Open market or private sale
|
Direct |
13,316
-15.13%
|
$199,740
$15.0 P/Share
|
|
Jan 19
2024
|
Ezio Bonvini Sr VP, Research & CSO |
SELL
Open market or private sale
|
Direct |
13,316
-13.15%
|
$159,792
$12.0 P/Share
|
|
Dec 20
2023
|
Ezio Bonvini Sr VP, Research & CSO |
SELL
Open market or private sale
|
Direct |
18,880
-15.71%
|
$188,800
$10.08 P/Share
|
|
Oct 02
2023
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
150,000
+1.49%
|
$600,000
$4.46 P/Share
|
|
Sep 07
2023
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
200,000
+2.0%
|
$1,000,000
$5.26 P/Share
|
|
Aug 30
2023
|
Edward Hurwitz Director |
BUY
Open market or private purchase
|
Direct |
15,000
+31.2%
|
$60,000
$4.91 P/Share
|
|
Mar 10
2023
|
Jeffrey Stuart Peters Senior VP and General Counsel |
SELL
Open market or private sale
|
Direct |
5,372
-100.0%
|
$32,232
$6.03 P/Share
|
|
Feb 22
2023
|
Ezio Bonvini Sr VP, Research & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,619
-2.92%
|
$21,714
$6.55 P/Share
|
|
Feb 22
2023
|
Ezio Bonvini Sr VP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+7.04%
|
-
|
|
Feb 22
2023
|
Jeffrey Stuart Peters Senior VP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,378
-38.61%
|
$20,268
$6.55 P/Share
|
|
Feb 22
2023
|
Jeffrey Stuart Peters Senior VP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
8,750
+50.0%
|
-
|
|
Feb 14
2023
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
500,000
+4.96%
|
$2,500,000
$5.07 P/Share
|
|
Jan 19
2023
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
150,000
+1.63%
|
$750,000
$5.3 P/Share
|
|
Dec 27
2022
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
200,000
+2.19%
|
$1,000,000
$5.61 P/Share
|
|
Dec 23
2022
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
200,000
+2.24%
|
$1,000,000
$5.88 P/Share
|
|
Nov 22
2022
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
300,000
+3.4%
|
$1,500,000
$5.96 P/Share
|
|
Oct 28
2022
|
Eric Blasius Risser Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+13.72%
|
$8,500
$1.51 P/Share
|
|
Oct 24
2022
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
250,000
+2.95%
|
$1,000,000
$4.36 P/Share
|
|
Oct 21
2022
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
250,000
+3.04%
|
$1,000,000
$4.63 P/Share
|
|
Oct 20
2022
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
285,977
+3.57%
|
$1,143,908
$4.0 P/Share
|
|
Oct 19
2022
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
168,422
+2.21%
|
$505,266
$3.7 P/Share
|
|
Jun 15
2022
|
James Karrels SVP, CFO and Secretary |
BUY
Open market or private purchase
|
Direct |
40,000
+17.26%
|
$80,000
$2.47 P/Share
|
|
May 16
2022
|
Scott Koenig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
53,265
+4.83%
|
$53,265
$1.51 P/Share
|
|
May 14
2022
|
Ezio Bonvini Sr VP, Research & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,666
-1.44%
|
$6,664
$4.16 P/Share
|
|
May 14
2022
|
Ezio Bonvini Sr VP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.13%
|
-
|